ResearcherUniversity of FlorenceActive in the last 2 years
Martina Catalano
Matched on ORCID iD 0000-0003-1856-2848; OpenAlex author ID A5004699983. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2020: 3 papers · 2021: none · 2022: 3 papers · 2023: 2 papers · 2024: 1 paper
Papers 9
- Perineural invasion score system and clinical outcomes in resected pancreatic cancer patients. First author DOI 10.1016/j.pan.2024.03.004↗
- Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine. First author DOI 10.1080/1120009x.2023.2190712↗
- Prognostic value of alkaline phosphatase and gamma-glutamyl transferase in patients with metastatic pancreatic cancer. Co-author DOI 10.2217/fon-2023-0137↗
- The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-022-12214-4↗
- Risk Factors for Nab-Paclitaxel and Gemcitabine-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer. Co-author DOI 10.1159/000524868↗
- Capecitabine as a Second-line Treatment for Older Patients with Pancreatic Cancer. Co-author DOI 10.2174/1389201023666220307090450↗
- Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-020-76465-9↗
- FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.2147/cmar.s267393↗
- Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study. Co-author DOI 10.2174/1568009620999200918122426↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Giandomenico Roviello · 9 shared papers, 2020–2024 · strength 1.48
- Paper Perineural invasion score system and clinical outcomes in resected pancreatic cancer patients. DOI 10.1016/j.pan.2024.03.004↗
- Paper Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-p… DOI 10.1080/1120009x.2023.2190712↗
- Paper The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients wi… DOI 10.1038/s41598-022-12214-4↗
- Monica Ramello · 8 shared papers, 2020–2023 · strength 1.29
- Paper Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-p… DOI 10.1080/1120009x.2023.2190712↗
- Paper The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients wi… DOI 10.1038/s41598-022-12214-4↗
- Paper Risk Factors for Nab-Paclitaxel and Gemcitabine-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer. DOI 10.1159/000524868↗
- Roberto Petrioli · 8 shared papers, 2020–2023 · strength 1.29
- Paper Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-p… DOI 10.1080/1120009x.2023.2190712↗
- Paper The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients wi… DOI 10.1038/s41598-022-12214-4↗
- Paper Risk Factors for Nab-Paclitaxel and Gemcitabine-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer. DOI 10.1159/000524868↗
- Giuseppe Aprile · 4 shared papers, 2022–2023 · strength 0.74
- Paper The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients wi… DOI 10.1038/s41598-022-12214-4↗
- Paper Risk Factors for Nab-Paclitaxel and Gemcitabine-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer. DOI 10.1159/000524868↗
- Paper Capecitabine as a Second-line Treatment for Older Patients with Pancreatic Cancer. DOI 10.2174/1389201023666220307090450↗
- Alberto D’Angelo · 3 shared papers, 2020–2023 · strength 0.40
- Paper Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-p… DOI 10.1080/1120009x.2023.2190712↗
- Paper Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: … DOI 10.2174/1568009620999200918122426↗
- Paper Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic c… DOI 10.1038/s41598-020-76465-9↗
- Enrico Mini · 3 shared papers, 2020–2023 · strength 0.39
- Paper Prognostic value of alkaline phosphatase and gamma-glutamyl transferase in patients with metastatic pancreatic cancer. DOI 10.2217/fon-2023-0137↗
- Paper Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: … DOI 10.2174/1568009620999200918122426↗
- Paper Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic c… DOI 10.1038/s41598-020-76465-9↗
- Filippo Nozzoli · 1 shared paper, 2024 · strength 0.20
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.